Current stage -Stage IV - Page 2 of 44 Posts on Medivizor

Evaluating the effectiveness of abemaciclib alone or in combination with tamoxifen in patients with HR+, HER2– metastatic breast cancer resistant to hormone therapy.

Posted by Medivizor on Jan 8, 2023 in Breast cancer | 0 comments

In a nutshell This study evaluated the effectiveness of abemaciclib (Verzenio) alone or in combination with tamoxifen (Nolvadex) in patients with hormone receptor-positive (HR+)/HER2-negative (HER2-) metastatic breast cancer (BC) resistant to hormone therapy. The data showed that abemaciclib in combination with tamoxifen was more effective in improving...

Evaluating the effectiveness and safety of anlotinib as a third-line treatment in patients with advanced NSCLC.

Posted by Medivizor on Dec 31, 2022 in Lung cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of anlotinib (AL3818) as a third-line treatment in patients with advanced non-small cell lung cancer (NSCLC). The data showed that anlotinib as a third-line treatment was effective with manageable side effects in these patients. Some background NSCLC is the most common form of lung...

Evaluating the effectiveness and safety of ramucirumab and pembrolizumab versus standard of care in previously treated patients with advanced NSCLC.

Posted by Medivizor on Dec 9, 2022 in Lung cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety outcomes of ramucirumab (Cyramza) and pembrolizumab (Keytruda) versus standard of care (SOC) in previously treated patients with advanced non-small cell lung cancer (NSCLC). The data showed that ramucirumab and pembrolizumab significantly improved overall survival compared with SOC in...

Evaluating the health-related quality of life outcomes of second-line chemotherapy combined with either bevacizumab or cetuximab in patients with advanced colorectal cancer.

Posted by Medivizor on Dec 4, 2022 in Colorectal cancer | 0 comments

In a nutshell This study evaluated the health-related quality of life (HR-QoL) outcomes of second-line chemotherapy combined with either bevacizumab (Avastin) or with cetuximab (Erbitux) in patients with advanced colorectal cancer with wild-type KRAS. This study concluded that the HR-QoL outcomes were similar with both treatments in these...

Evaluating the effects of olaparib plus abiraterone regarding patient-reported outcomes in patients with metastatic castration-resistant prostate cancer patients

Posted by Medivizor on Nov 22, 2022 in Prostate cancer | 0 comments

In a nutshell This study compared the effects on patient-reported outcomes (PROs) of using olaparib (Lynparza) plus abiraterone (Zytiga) versus placebo plus abiraterone for the treatment of metastatic castration-resistant prostate cancer (mCRPC). The study found that adding olaparib to abiraterone in these patients did not...

Evaluating the effectiveness and safety of elacestrant versus standard hormonal therapy in patients with ER+/HER2- advanced BC.

Posted by Medivizor on Oct 7, 2022 in Breast cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of elacestrant (RAD1901) versus standard hormonal therapy in patients with estrogen receptor-positive (ER+) and HER2-negative (HER2-) advanced breast cancer (BC). The data showed that elacestrant significantly improved survival without cancer worsening with manageable side effects in these...

Evaluating the long-term effectiveness and safety of palbociclib plus fulvestrant treatment in patients with HR+/HER2- advanced BC.

Posted by Medivizor on Sep 18, 2022 in Breast cancer | 0 comments

In a nutshell This study evaluated the long-term effectiveness and safety of palbociclib (Ibrance) plus fulvestrant (Faslodex) in patients with hormone receptor-positive (HR+) and HER2-negative (HER2-) advanced breast cancer (BC). The data showed that adding palbociclib to fulvestrant was safe and significantly improved the overall survival over the...

Evaluating the long-term outcomes of radiotherapy added to standard therapy for men with metastatic prostate cancer.

Posted by Medivizor on Sep 18, 2022 in Prostate cancer | 0 comments

In a nutshell The study investigated whether radiotherapy (RT) addedd to standard of care (SOC) treatment would be beneficial for men with metastatic (spread) prostate cancer (mPC). The study showed that adding RT to SOC improved the survival of men with low burden (defined as fewer than 10 lesions, no greater than 3cm in diameter) mPC. Some...

Evaluating the effectiveness and safety of darolutamide in combination with androgen deprivation therapy and docetaxel for metastatic hormone-sensitive prostate cancer.

Posted by Medivizor on Jul 16, 2022 in Prostate cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of darolutamide (Nubeqa) in combination with androgen deprivation therapy (ADT) and docetaxel (Taxotere) for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC). The data showed that darolutamide in combination with ADT and docetaxel significantly improved the overall...

Evaluating the effectiveness and safety of 225Ac-PSMA-617 for the treatment of patients with metastatic castration-resistant prostate cancer.

Posted by Medivizor on Jun 26, 2022 in Prostate cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of actinium-225 [225Ac]-PSMA-617 (225AcPSMA) for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). The data showed that 225AcPSMA was effective with manageable side effects for these patients. Some background Prostate cancer (PC) often grows in...

How effective is an immunomodulatory vaccine against PD-L1 /IDO in combination with nivolumab for the treatment of metastatic melanoma?

Posted by Medivizor on Jun 1, 2022 in Melanoma | 0 comments

In a nutshell The study aimed to evaluate the safety and effectiveness of an immunomodulatory IDO/PD-L1 targeting peptide vaccine (IO102/IO103) combined with nivolumab (Opdivo) in patients with metastatic melanoma (MM). The study concluded that the IO102/IO103 vaccine combined with nivolumab is safe and effective in these...

Evaluating the effectiveness and safety of 225Ac-PSMA-617 after treatment with androgen deprivation therapy in patients with metastatic castration-resistant prostate cancer.

Posted by Medivizor on May 31, 2022 in Prostate cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of actinium-225 [225Ac]-PSMA-617 (225AcPSMA) after treatment with androgen deprivation therapy (ADT) in patients with metastatic castration-resistant prostate cancer (mCRPC). The data showed that 225AcPSMA treatment showed a higher response with manageable effects in these patients. Some...

Current stage -Stage IV Posts on Medivizor

Evaluating the effectiveness of abemaciclib alone or in combination with tamoxifen in patients with HR+, HER2– metastatic breast cancer resistant to hormone therapy.

Evaluating the effectiveness and safety of anlotinib as a third-line treatment in patients with advanced NSCLC.

Evaluating the effectiveness and safety of ramucirumab and pembrolizumab versus standard of care in previously treated patients with advanced NSCLC.

Evaluating the health-related quality of life outcomes of second-line chemotherapy combined with either bevacizumab or cetuximab in patients with advanced colorectal cancer.

Evaluating the effects of olaparib plus abiraterone regarding patient-reported outcomes in patients with metastatic castration-resistant prostate cancer patients

Evaluating the effectiveness and safety of elacestrant versus standard hormonal therapy in patients with ER+/HER2- advanced BC.

Evaluating the long-term effectiveness and safety of palbociclib plus fulvestrant treatment in patients with HR+/HER2- advanced BC.

Evaluating the long-term outcomes of radiotherapy added to standard therapy for men with metastatic prostate cancer.

Evaluating the effectiveness and safety of darolutamide in combination with androgen deprivation therapy and docetaxel for metastatic hormone-sensitive prostate cancer.

Evaluating the effectiveness and safety of 225Ac-PSMA-617 for the treatment of patients with metastatic castration-resistant prostate cancer.

How effective is an immunomodulatory vaccine against PD-L1 /IDO in combination with nivolumab for the treatment of metastatic melanoma?

Evaluating the effectiveness and safety of 225Ac-PSMA-617 after treatment with androgen deprivation therapy in patients with metastatic castration-resistant prostate cancer.

Categories

Recent Posts

Archives

Current stage -Stage IV Posts on Medivizor

Categories

Recent Posts

Archives

Thanks for your interest in Medivizor

Invalid email